Psyence Biomedical Ltd. (PBM) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Psyence Biomedical Ltd. (PBM:NASDAQ), powered by AI.

Current Price
$11.30
P/E Ratio
0.0
Market Cap
43,788
Sector
Healthcare
What is the Psyence Biomedical Ltd. stock price forecast?

Psyence Biomedical Ltd. is currently trading at $11.30. View real-time AI analysis on Alpha Lenz.

What is Psyence Biomedical Ltd. insider trading activity?

View the latest insider trading data for Psyence Biomedical Ltd. on Alpha Lenz.

What is Psyence Biomedical Ltd.'s P/E ratio?

Psyence Biomedical Ltd.'s P/E ratio is 0.0.

Psyence Biomedical Ltd.

NASDAQ · PBM
$11.30
Ask about Psyence Biomedical Ltd.'s future dividend policy...
Alpha Chat Insight

Psyence Biomedical Ltd. trades at a P/E of 0.0 (undervalued) with modest ROE of -47.6%.

Ask for details

Company Overview

Psyence Biomedical Ltd. is a company that specializes in the research and development of psychedelic-based therapeutics aimed at addressing mental health challenges. Its primary function is to explore the potential of psychedelics in treating conditions such as depression, PTSD, anxiety, and substance use disorders. The firm is at the forefront of innovative healthcare solutions, as it integrates cutting-edge scientific research with traditional medicinal knowledge to develop safe and effective treatment options. Notably, Psyence Biomedical collaborates with healthcare professionals, researchers, and regulatory bodies to ensure that their therapeutic offerings meet stringent safety and efficacy standards. As part of the burgeoning psychedelic industry, the company plays a significant role in potentially revolutionizing mental health care through novel approaches. Its efforts contribute to expanding the understanding of psychedelics in medicine while also addressing a growing demand for alternative and complementary mental health therapies. Psyence Biomedical's work signifies a transformative shift in the perception and utilization of psychedelics, highlighting the asset’s contribution to advancing psychiatric treatments and its growing importance in the pharmaceutical market.

CEOMr. Jody Aufrichtig
SectorHealthcare
IndustryBiotechnology
Employees12

Company Statistics

FY 2025

Profile

$43.79KMarket Cap
$0.00Revenue
0.00Shares Out
12Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

0.04P/E
0.01P/B
N/AEV/Sales
-12.18EV/EBITDA
-0.01P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

23.95%ROA
-47.61%ROE
24.17%ROIC

Financial Health

$6.14MCash & Cash Equivalents
$-5.54MNet Debt
8.84%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Psyence Biomedical Ltd. (ticker: PBM) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 12 employees. Market cap is $43,788.

The current price is $11.3 with a P/E ratio of 0.04x and P/B of 0.01x.

ROE is -47.61%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Psyence Biomedical Ltd. (Healthcare) Stock Forecast & Analysis $11.30 | Alpha Lenz